Piedmont Oncology Enrolls First US Patients in MOMENTUM-1 Cancer Trial

The clinical trial is evaluating a novel therapy for adult patients with progressive intracranial meningioma.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Piedmont Oncology, via Piedmont Atlanta Hospital, has become the first site in the United States to enroll patients in the MOMENTUM-1 clinical trial. The trial is designed to evaluate a new therapy for adult patients with progressive intracranial meningioma, a type of brain tumor.

Why it matters

The MOMENTUM-1 trial represents a potential major advance in the treatment of meningiomas, which are difficult-to-treat brain tumors. Piedmont's participation in this trial demonstrates its commitment to providing patients access to the latest innovative cancer therapies.

The details

The MOMENTUM-1 trial involves the use of lutetium Lu-177 dotate, a radioactive drug approved by the FDA to treat other rare cancers. The trial is a partnership between the RTOG Foundation, a nonprofit focused on improving cancer outcomes, and Novartis, the manufacturer of the drug. Dr. Adam Nowlan of Piedmont Physicians Radiation Oncology Atlanta is serving as the local principal investigator.

  • The trial began enrolling patients on March 5, 2026.

The players

Piedmont Oncology

A cancer care provider within the Piedmont Healthcare system, which operates hospitals, clinics, and physician practices across Georgia.

Walter J. 'Wally' Curran, Jr., M.D., FACR, FASCO

The Whitaker Endowed Chief of Piedmont Oncology.

Adam Nowlan, M.D., M.P.H.

A member of the clinical trials team at the Piedmont Brain Tumor Center and the local principal investigator for the MOMENTUM-1 trial.

RTOG Foundation

A nonprofit dedicated to improving outcomes for cancer patients through the conduct of practice-changing clinical trials.

Novartis

The manufacturer of lutetium Lu-177 dotate, the drug being evaluated in the MOMENTUM-1 trial.

Got photos? Submit your photos here. ›

What they’re saying

“We are proud to offer this innovative treatment to Piedmont Oncology patients. Piedmont cares for patients from all 50 states and the ability to offer this trial demonstrates that the quality of our system ranks among the best in the country.”

— Walter J. 'Wally' Curran, Jr., M.D., FACR, FASCO, Whitaker Endowed Chief of Piedmont Oncology

“The treatment offered in the MOMENTUM-1 trial could represent a major advance for patients with meningiomas, and we are excited to investigate this therapy for these patients.”

— Adam Nowlan, M.D., M.P.H., Member of the clinical trials team at the Piedmont Brain Tumor Center

What’s next

The MOMENTUM-1 trial is currently enrolling patients at Piedmont Oncology, and the results of the study will be closely watched for their potential to advance the treatment of meningioma.

The takeaway

Piedmont Oncology's participation in the MOMENTUM-1 trial demonstrates its commitment to providing patients access to the latest innovative cancer therapies, further solidifying its reputation as a leading cancer care provider in Georgia.